Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure.
Chronic heart failure
High-sensitivity troponin T
NT-proBNP
Prognosis
Sex
Women
sST2
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
17
02
2022
received:
30
12
2021
accepted:
02
03
2022
pubmed:
6
5
2022
medline:
20
7
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
To define plasma concentrations, determinants, and optimal prognostic cut-offs of soluble suppression of tumorigenesis-2 (sST2), high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in women and men with chronic heart failure (HF). Individual data of patients from the Biomarkers In Heart Failure Outpatient Study (BIOS) Consortium with sST2, hs-cTnT, and NT-proBNP measured were analysed. The primary endpoint was a composite of 1 year cardiovascular death and HF hospitalization. The secondary endpoints were 5 year cardiovascular and all-cause death. The cohort included 4540 patients (age 67 ± 12 years, left ventricular ejection fraction 33 ± 13%, 1111 women, 25%). Women showed lower sST2 (24 vs. 27 ng/mL, P < 0.001) and hs-cTnT level (15 vs. 20 ng/L, P < 0.001), and similar concentrations of NT-proBNP (1540 vs. 1505 ng/L, P = 0.408). Although the three biomarkers were confirmed as independent predictors of outcome in both sexes, the optimal prognostic cut-off was lower in women for sST2 (28 vs. 31 ng/mL) and hs-cTnT (22 vs. 25 ng/L), while NT-proBNP cut-off was higher in women (2339 ng/L vs. 2145 ng/L). The use of sex-specific cut-offs improved risk prediction compared with the use of previously standardized prognostic cut-offs and allowed to reclassify the risk of many patients, to a greater extent in women than men, and for hs-cTnT than sST2 or NT-proBNP. Specifically, up to 18% men and up to 57% women were reclassified, by using the sex-specific cut-off of hs-cTnT for the endpoint of 5 year cardiovascular death. In patients with chronic HF, concentrations of sST2 and hs-cTnT, but not of NT-proBNP, are lower in women. Lower sST2 and hs-cTnT and higher NT-proBNP cut-offs for risk stratification could be used in women.
Identifiants
pubmed: 35510529
doi: 10.1002/ehf2.13883
pmc: PMC9288762
doi:
Substances chimiques
Biomarkers
0
IL1RL1 protein, human
0
Interleukin-1 Receptor-Like 1 Protein
0
Peptide Fragments
0
Troponin T
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2084-2095Informations de copyright
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
J Am Coll Cardiol. 2002 Sep 4;40(5):976-82
pubmed: 12225726
J Neurochem. 2008 Jun 1;105(6):2477-88
pubmed: 18346198
J Card Fail. 2013 Mar;19(3):156-62
pubmed: 23482075
Eur J Prev Cardiol. 2021 Aug 9;28(9):948-955
pubmed: 34402870
JACC Heart Fail. 2021 Sep;9(9):653-663
pubmed: 34246607
Am J Med. 2015 Mar;128(3):276-82
pubmed: 25447612
Clin Pharmacol Ther. 2021 Aug;110(2):498-507
pubmed: 33630302
Circ Heart Fail. 2014 Jan;7(1):96-103
pubmed: 24284025
Sci Adv. 2020 May 13;6(20):eaay6191
pubmed: 32426492
JACC Heart Fail. 2017 Apr;5(4):280-286
pubmed: 27816512
Europace. 2019 Mar 1;21(3):366-376
pubmed: 30351414
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Clin Sci (Lond). 2001 Nov;101(5):447-53
pubmed: 11672449
Eur J Heart Fail. 2021 Mar;23(3):352-380
pubmed: 33605000
Sci Rep. 2018 Jan 18;8(1):1080
pubmed: 29348420
Eur J Heart Fail. 2020 May;22(5):775-788
pubmed: 32220046
Clin Biochem. 2016 Apr;49(6):467-471
pubmed: 26768729
J Am Coll Cardiol. 2018 Nov 6;72(19):2309-2320
pubmed: 30384887
J Am Coll Cardiol. 2019 Jan 8;73(1):29-40
pubmed: 30621948
JACC Heart Fail. 2017 Apr;5(4):287-296
pubmed: 28189578
Am J Cardiol. 2015 Apr 2;115(7 Suppl):8B-21B
pubmed: 25697919
Med Sci Monit. 2011 Sep;17(9):BR266-73
pubmed: 21873939
JAMA. 2020 Aug 04;324(5):488-504
pubmed: 32749493
Cardiovasc Diabetol. 2016 Nov 3;15(1):151
pubmed: 27809845
Circulation. 2012 Jan 17;125(2):280-8
pubmed: 22139751
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
Circ Heart Fail. 2014 May;7(3):418-26
pubmed: 24622243
J Geriatr Cardiol. 2011 Mar;8(1):15-23
pubmed: 22783280
Eur J Heart Fail. 2018 Aug;20(8):1205-1214
pubmed: 29855124
Am J Kidney Dis. 2010 Apr;55(4):622-7
pubmed: 20338463
Cardiovasc Res. 1999 Mar;41(3):524-31
pubmed: 10435024
Card Fail Rev. 2019 Feb;5(1):44-49
pubmed: 30847245
JACC Heart Fail. 2014 Feb;2(1):65-72
pubmed: 24622120
Eur J Heart Fail. 2015 Oct;17(10):1006-14
pubmed: 26472682
Clin Biochem. 2015 Dec;48(18):1337-40
pubmed: 26277636
J Am Coll Cardiol. 2019 Mar 26;73(11):1288-1296
pubmed: 30898204
Am Heart J. 2013 Aug;166(2):357-364.e2
pubmed: 23895820
Eur J Heart Fail. 2019 Jun;21(6):715-731
pubmed: 31222929
Eur J Heart Fail. 2017 Dec;19(12):1586-1596
pubmed: 28295985
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Chem. 2012 Dec;58(12):1673-81
pubmed: 23065477
Nat Rev Dis Primers. 2017 Aug 24;3:17058
pubmed: 28836616
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Eur J Prev Cardiol. 2022 May 27;29(8):1233-1243
pubmed: 33963839
Front Cardiovasc Med. 2021 Jan 05;7:617705
pubmed: 33469552
Biomarkers. 2021 Nov;26(7):639-646
pubmed: 34269635
Eur Heart J. 2019 Dec 14;40(47):3859-3868c
pubmed: 31800034
Eur J Heart Fail. 2017 Dec;19(12):1638-1647
pubmed: 28849609
Clin Res Cardiol. 2015 Apr;104(4):334-41
pubmed: 25373384
ESC Heart Fail. 2022 Aug;9(4):2084-2095
pubmed: 35510529
Clin Chem. 2017 Sep;63(9):1457-1464
pubmed: 28630238
Circulation. 2018 Jan 16;137(3):286-297
pubmed: 29335288
Circ Heart Fail. 2018 Nov;11(11):e005312
pubmed: 30571192